利伐沙班治疗肺栓塞高危患者的临床效果观察  

Clinical Effect of Rivaroxaban in the Treatment of High-risk Patients with Pulmonary Embolism

作　　者：雷万锋 Lei Wanfeng(Department of Respiratory,Beijing Huairou Hospital,Beijing 101400,China)

机构地区：[1]北京怀柔医院呼吸科,北京101400

出　　处：《中外医药研究》2024年第17期27-29,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

基　　金：2020年县区级公立医院薄弱专科建设项目(编号:HCZX-2020-A0001)。

摘　　要：目的:研究利伐沙班治疗肺栓塞高危患者的临床效果。方法:选取2018年1月—2023年1月北京怀柔医院呼吸科收治的肺栓塞高危患者90例作为研究对象,依据双盲法分为常规组和科研组,各45例。常规组给予低分子肝素联合华法林钠,科研组给予低分子肝素联合利伐沙班治疗。比较两组临床指标、临床疗效、症状消退时间及不良事件发生情况。结果:治疗前,两组临床指标比较,差异无统计学意义(P>0.05);治疗后,科研组动脉血氧分压高于常规组,血清肌钙白I、脑钠肽、肺动脉收缩压、D-二聚体低于常规组,差异有统计学意义(P<0.05)。科研组总有效率高于常规组,差异有统计学意义(P<0.05)。科研组呼吸困难、胸痛、发绀、咯血消退时间短于常规组,差异有统计学意义(P<0.05)。治疗前,两组不良事件发生率比较,差异无统计学意义(P>0.05);治疗后,科研组不良事件发生率低于常规组,差异有统计学意义(P<0.05)。结论:利伐沙班治疗肺栓塞高危患者,可提高其动脉血氧分压、临床疗效,减轻症状并避免不良事件。Objective:To study the clinical effect of rivaroxaban in the treatment of high-risk patients with pulmonary embolism.Methods:A total of ninety high-risk patients with pulmonary embolism admitted to the respiratory department of Beijing Huairou Hospital from January 2018 to January 2023 were selected as the study objects,and were divided into routine group and research group according to double-blind method,with forty-five cases in each group.The routine group was given low molecular weight heparin combined with warfarin sodium,and the research group was given low molecular weight heparin combined with rivaroxaban.The clinical indexes,clinical efficacy,symptom resolution time and adverse events were compared between the two groups.Results:Before treatment,there was no significant difference in clinical indexes between the two groups(P>0.05);after treatment,the partial blood oxygen pressure of the research group was higher than that of the routine group,and the serum muscle calcium white I,brain natriuretic peptide,pulmonary artery systolic blood pressure and D-dimer were lower than that of the routine group,the difference was statistically significant(P<0.05);the total effective rate of the research group was higher than that of the routine group,and the difference was statistically significant(P<0.05);dyspnea,chest pain,cyanosis and hemoptysis in the research group were shorter than those in the routine group,and the difference was statistically significant(P<0.05);before treatment,there was no significant difference in the incidence of adverse events between the two groups(P>0.05);after treatment,the incidence of adverse events in the research group was lower than that in the routine group,and the difference was statistically significant(P<0.05).Conclusion:In the treatment of high-risk patients with pulmonary embolism,rivaroxaban can improve the partial pressure of arterial blood oxygen,reduce symptoms and avoid adverse events.

关 键 词：利伐沙班 肺栓塞高危组 溶栓 不良事件 

分 类 号：R563.5[医药卫生—呼吸系统]